Do you want to read an article? Please log in or register.
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors
Further Publications
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
doi: 10.1007/s00432-018-2805-3.
Further Publications
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
JAMA Oncol.
Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF, Legallois D, Milliez PU, Lelong-Boulouard V, Alexandre J
doi: 10.1001/jamaoncol.2020.0726.
Lung, Respiratory and Thoracic Cancer
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer
JAMA Oncol.
Shankar B, Zhang J, Naqash AR, Forde PM, Feliciano JL, Marrone KA, Ettinger DS, Hann CL, Brahmer JR, Ricciuti B, Owen D, Toi Y, Walker P, Otterson GA, Patel SH, Sugawara S, Naidoo J
doi: 10.1001/jamaoncol.2020.5012.
Radio-Oncology
Safety of Thoracic Radiotherapy in Patients with Prior Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Ann Oncol.
Shaverdian N, Beattie J, Thor M, Offin M, Shepherd AF, Gelblum DY, Wu AJ, Simone CB 2nd, Hellmann MD, Chaft JE, Rimner A, Gomez DR
doi: 10.1016/j.annonc.2020.09.016.
Gastrointestinal CancerSkin Cancer
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Cancer Treat Rev.
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C
doi: 10.1016/j.ctrv.2017.06.002.
COMMENTED
Further Publications
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
RECOMMENDED
Radio-Oncology
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy
★ 1
Recommended by
Alexander Meisel, Faculty Member
Eur J Cancer.
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, Gostian AO, Frey B, Gaipl US, Zhou JG, Fietkau R, Hecht M
doi: 10.1016/j.ejca.2020.09.001.Visit the original publication at ncbi.nlm.nih.gov
Further Publications
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy
★ 3
Recommended and commented by
Prof. Dr Dr Sacha Rothschild, Faculty Member
Eur J Cancer
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O
doi: 10.1016/j.ejca.2021.03.010
Further Publications
Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
JAMA Oncol.
Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O
doi: 10.1001/jamaoncol.2019.1022.